The psychosis analysis in real-world on a cohort of large-scale patients with schizophrenia

Background With China experiencing unprecedented economic development and social change over the past three decades, Chinese policy makers and health care professionals have come to view mental health as an important outcome to monitor. Our study conducted an epidemiological study of psychosis in Guangdong province, with 20 million real-world follow-up records in the last decade. Methods Data was collected from Guangdong mental health information platform from 2010 to 2019, which had standardized disease registration and follow-up management for nearly 600,000 patients with six categories of mental diseases and 400,000 patients with schizophrenia. We conducted clinical staging for the disease course of the patients and divided the data with various factors into different stages of disease. Quantitative analysis was utilized to investigate the high relevant indicators to the disease. The results were projected on geography map for regional distribution analysis. Results The majority cases of mental disease incidence were between the age of 15 and 29, while the peak age for both male and female was between 20 to 24 years old. The disease course with the largest number of patients’ cases was between 5 to 10 years. The therapeutic effect of patients gradually decreased with the development of disease course, while the risk increased with the disease course. The analysis of influencing factors showed that poor economic conditions incurred higher risk scores, and good medication adherence was effective in improving treatment outcomes. In addition, receiving good education contributed to the reduction of the risk of schizophrenia and the improvement of the efficiency of early treatment. Through the analysis of regional distribution of schizophrenia disease, developed economic conditions and favorable resource conditions could promote the reduction of disease risk, while in economically backward regions, it often accompanied with lower therapeutic effect and higher disease risk. Conclusions Certain demographic factors had a relatively prominent impact on the therapeutic effect and risk of schizophrenia, such as high-quality medication adherence. Therapeutic effect and risk were highly correlated. Backward economic conditions often associated with poor efficacy and higher risk assessment, and the developed economy and better medical resource are beneficial for the treatment of psychotic.

[1]  Hong Wang,et al.  The China Mental Health Survey: II. Design and field procedures , 2016, Social Psychiatry and Psychiatric Epidemiology.

[2]  J. Zhai,et al.  An investigation of economic costs of schizophrenia in two areas of China , 2013, International Journal of Mental Health Systems.

[3]  Peter B. Jones,et al.  Association of Environment With the Risk of Developing Psychotic Disorders in Rural Populations , 2017, JAMA psychiatry.

[4]  Keyong Dong,et al.  Medical insurance system evolution in China , 2009 .

[5]  Peter B. Jones,et al.  International incidence of psychotic disorders, 2002–17: a systematic review and meta-analysis , 2019, The Lancet. Public health.

[6]  C. Pantelis,et al.  A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis , 2016, Neuroscience & Biobehavioral Reviews.

[7]  Bao-yun Liang,et al.  The prevalence of schizophrenia in mainland China: evidence from epidemiological surveys , 2014, Acta psychiatrica Scandinavica.

[8]  J. Li,et al.  The family economic status and outcome of people with schizophrenia in Xinjin, Chengdu, China: 14-year follow-up study , 2017, The International journal of social psychiatry.

[9]  Guoqin Zhang,et al.  Urbanization and health in China, thinking at the national, local and individual levels , 2016, Environmental Health.

[10]  A. Furnham,et al.  Awareness of schizophrenia and intellectual disability and stigma across ethnic groups in the UK , 2013, Psychiatry Research.

[11]  James G. Scott,et al.  Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016 , 2018, Schizophrenia bulletin.

[12]  Qichang Shi,et al.  Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey , 2009, The Lancet.

[13]  M. De Hert,et al.  Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review , 2013, Therapeutic advances in psychopharmacology.

[14]  T. B. Üstün,et al.  Age of onset of mental disorders: a review of recent literature , 2007, Current opinion in psychiatry.

[15]  V. Janout,et al.  Epidemiology and risk factors of schizophrenia. , 2016, Neuro endocrinology letters.

[16]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[17]  E. Theodoratou,et al.  Causes of accidental childhood deaths in China in 2010: A systematic review and analysis , 2015, Journal of global health.

[18]  Wei Wang,et al.  Online Supplementary Document , 2014 .

[19]  Jayashri Kulkarni,et al.  Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review , 2012, Schizophrenia research and treatment.

[20]  Hong Wang,et al.  The China Mental Health Survey (CMHS): I. background, aims and measures , 2016, Social Psychiatry and Psychiatric Epidemiology.

[21]  S. Saha,et al.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? , 2007, Archives of general psychiatry.

[22]  P. Mortensen,et al.  Parental socio-economic status and risk of first admission with schizophrenia , 2004, Social Psychiatry and Psychiatric Epidemiology.

[23]  P. Mortensen,et al.  Parental socio-economic status and risk of first admission with schizophrenia , 2004, Social psychiatry and psychiatric epidemiology.

[24]  E. Susser,et al.  New directions in the epidemiology of schizophrenia , 2009, The Medical journal of Australia.

[25]  R. Kessler,et al.  Twelve-month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China , 2005, Psychological Medicine.

[26]  Xin Yu,et al.  Mental health system in China: history, recent service reform and future challenges , 2011, World psychiatry : official journal of the World Psychiatric Association.

[27]  R. Kahn,et al.  Sex differences in the risk of schizophrenia: evidence from meta-analysis. , 2003, Archives of general psychiatry.

[28]  S. Potkin,et al.  Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia , 2015, Schizophrenia Research.

[29]  J. Mcgrath The surprisingly rich contours of schizophrenia epidemiology. , 2007, Archives of general psychiatry.

[30]  H. Whiteford,et al.  Pragmatic Psychiatric Epidemiology—If You Can’t Count It, It Won’t Count , 2018, JAMA psychiatry.

[31]  A. Jablensky,et al.  Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders , 2016, The Australian and New Zealand journal of psychiatry.

[32]  T. Vos,et al.  Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010 , 2014, Epidemiology and Psychiatric Sciences.

[33]  H. Inskip,et al.  Twenty-five year mortality of a community cohort with schizophrenia , 2010, British Journal of Psychiatry.

[34]  T. Hu Perspectives: an international review of the national cost estimates of mental illness, 1990-2003. , 2006, The journal of mental health policy and economics.

[35]  B. Macmahon,et al.  Epidemiology: Principles and Methods , 1970 .

[36]  Peter B. Jones,et al.  The Epidemiology of First-Episode Psychosis in Early Intervention in Psychosis Services: Findings From the Social Epidemiology of Psychoses in East Anglia [SEPEA] Study. , 2017, The American journal of psychiatry.

[37]  Diana O Perkins,et al.  Predictors of noncompliance in patients with schizophrenia. , 2002, The Journal of clinical psychiatry.

[38]  Tao Li,et al.  Prevalence of mental disorders in China: a cross-sectional epidemiological study. , 2019, The lancet. Psychiatry.

[39]  C. Weijer,et al.  Helsinki discords: FDA, ethics, and international drug trials , 2009, The Lancet.

[40]  R. Kessler,et al.  Impaired Role Functioning and Treatment Rates for Mental Disorders and Chronic Physical Disorders in Metropolitan China , 2009, Psychosomatic medicine.

[41]  T. Treuer,et al.  The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy , 2013, ClinicoEconomics and outcomes research : CEOR.